NCT05151861 (REMOVE) is a Phase 4 clinical trial of Complete removal of pharmacological treatment in Heart Failure, sponsored by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia.

What drugs are being tested in NCT05151861?

Interventions in NCT05151861: Complete removal of pharmacological treatment, Control.

What condition does NCT05151861 study?

NCT05151861 studies Heart Failure.

Is NCT05151861 still recruiting?

NCT05151861 is currently status unknown. Last updated 30 December 2021.

Last reviewed 2021-12-30 · How we verify

NCT05151861: REMOVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy:

Status unknown Phase 4 Last updated 30 December 2021

What this trial tests

Phase 4 trial testing Complete removal of pharmacological treatment in Heart Failure in 60 participants. Status unknown.

Timeline

3 December 2021

Primary endpoint
15 November 2022

15 May 2023

Quick facts

Lead sponsor	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	3 December 2021
Primary completion	15 November 2022
Estimated completion	15 May 2023
Sites	1 location across Spain

Drugs / interventions tested

Complete removal of pharmacological treatment
Control

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia — full company profile →

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this randomized trial is to investigate the effect of the complete removal of pharmacological treatment in patients responding to cardiac resynchronization therapy with recuperated LVEF in terms of imaging parameters (changes in LVEF and LV volume), as well as, clinical parameters that translate into worsening of heart failure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Withdrawal of drug therapy in responders to cardiac resynchronization therapy: rationale and design of the REMOVE trial.
Pastor-Pérez FJ, Garrido-Bravo IP, Peñafiel-Verdú P, Fernández-Villa N, et al · · 2024 · PMID 38701881 · DOI 10.1016/j.rec.2024.02.021

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia trials

Trials by the same sponsor.

NCT07064811 — Standardized Resistance Training Program and Assessment System for Prostate Cancer Patients Receiving Androgen Deprivati · NA · not yet recruiting
NCT06646562 — Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months. · Phase 4 · recruiting
NCT06874907 — First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring. · recruiting
NCT06858345 — Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy · recruiting
NCT06713486 — Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndro · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05151861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Last refreshed: 30 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05151861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing